TY - JOUR T1 - Obstetric antiphospholipid syndrome JO - Revista Clínica Española (English Edition) T2 - AU - Esteve-Valverde,E. AU - Ferrer-Oliveras,R. AU - Alijotas-Reig,J. SN - 22548874 M3 - 10.1016/j.rceng.2015.11.003 DO - 10.1016/j.rceng.2015.11.003 UR - https://revclinesp.es/en-obstetric-antiphospholipid-syndrome-articulo-S2254887415001174 AB - Obstetric antiphospholipid syndrome is an acquired autoimmune disorder that is associated with various obstetric complications and, in the absence of prior history of thrombosis, with the presence of antiphospholipid antibodies directed against other phospholipids, proteins called cofactors or PL-cofactor complexes. Although the obstetric complications have been related to the procoagulant properties of antiphospholipid antibodies, pathological studies of human placenta have shown the proinflammatory capacity of antiphospholipid antibodies via the complement system and proinflammatory cytokines. There is no general agreement on which antiphospholipid antibodies profile (laboratory) confers the greatest obstetric risk, but the best candidates are categories I and IIa. Combined treatment with low doses of aspirin and heparin achieves good obstetric and maternal outcomes. In this study, we also review the therapeutic possibilities in refractory cases, although the likelihood of progressing to other autoimmune diseases is low. We briefly comment on incomplete obstetric antiphospholipid syndrome, also known as antiphospholipid antibody-mediated pregnancy morbidity syndrome. ER -